A Phase 3 interventional study of Rimegepant and Placebo in Temporomandibular Disorders (TMD), sponsored by Pfizer. Terminated at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-16.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Temporomandibular Joint Disorders with a site in United States — 17 open to participants now, 20 under way, none of them phase 3. Temporomandibular Joint Disorders · United States.
Among the 59 studies in Temporomandibular Joint Disorders with a site in United States, this one is the 13th largest by enrollment of the 46 interventional ones that give a count, is one of 6 that started in 2022, is one of 2 in phase 3, and was the 39th registered.
593 studies on the registry are indexed under Temporomandibular Joint Disorders; 149 are open to participants now.
Browse Temporomandibular Joint Disorders studies →17 of the 59 studies in Temporomandibular Joint Disorders with a site in United States are open now. Recruiting first, the newest first:
Arpana Church · Sites in United States
Ages 18–50 · Women only
University of Minnesota · Sites in United States
Ages 18+
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
University of Minnesota · Sites in United States
Ages 18–65
Theranica · Sites in United States
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Temporomandibular Joint Disorders studies recruiting now, 26 (35%) set no upper age limit and 45 (60%) stop at 75 or younger; 7 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2 · Phase 4 1
First in 1997; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 126 is above the median of 45 across 417 interventional studies indexed under Temporomandibular Joint Disorders.
Median enrollment 60 across the 46 interventional studies, 180 across the 11 observational. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Pfizer has 1 study filed under Temporomandibular Joint Disorders — fewer than ten, so there is no comparison to draw.
10 of the studies in Temporomandibular Joint Disorders with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06977100University of FloridaJournaling Intervention for Temporomandibular Disorder (TMD) and Chronic Overlapping Pain | 2026-11 |
| NCT07226505Loyola UniversityEffects of Core Strengthening Exercises for Treating TMD | 2026-12-01 |
| NCT06617494University of MinnesotaEndogenous Pain Inhibition Deficiency in Chronic TMD Pain | 2026-12-31 |
| NCT07153107University of MinnesotaR01_Pilot Jaw Muscle Phenotypes | 2027-01-12 |
| NCT04376333UConn HealthIndividualized Assessment and Treatment for TMD | 2027-03-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 59 studies in Temporomandibular Joint Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of Temporomandibular Disorders (TMD), which are medical conditions involving the temporomandibular joint (the joint connecting the jawbone to the skull) and surrounding muscles and tissues.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
* Subject has a minimum 3-month to a maximum 5-year history of temporomandibular disorder diagnosed by a healthcare provider.
Exclusion Criteria:
* Subject has an exclusionary headache, joint, pain, connective tissue, or developmental disorder.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of rimegepant 75 mg ODT
Drug: Rimegepant
One dose of matching placebo
Drug: Placebo
75 mg ODT
Also known as: BHV3000
matching placebo
Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2)
The SPID-2 was calculated by multiplying the pain intensity difference (PID) score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 2 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45-, 60-, 90- and 120-minutes post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-2 was: -12 (best) to 8 (worst). Lower SPID-2 score = more improvement from pain. SPID-2 Best is 2 hours\*-6 = -12 (assuming 0 pain intensity score \[pain-free\] for each timepoint) and 2) Worst is 2 hours\*4 = 8 (assuming 10 pain intensity score \[worst imaginable pain\] for each timepoint).
Time frame: Baseline (0 hours) to 2-hours post-dose
SPID From Baseline to 24-Hours Post-dose (SPID-24)
The SPID-24 was calculated by multiplying the PID score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 24 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45, 60, 90 and 120 minutes and 4-, 8-, and 24-hours post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-24 was: -144 (Best) to 96 (worst). Lower SPID-24 score = more improvement from pain. SPID-24 best and worst scores were calculated as: 1) Best is 24 hours\* -6 = -144 (assuming 0 pain intensity score for each timepoint) and 2) Worst is 24 hours\*4 = 96 (assuming 10 pain intensity score for each timepoint).
Time frame: Baseline (0 hours) to 24-hours post-dose
Change From Baseline in NRS Score at 2-Hours Post-Dose
TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."
Time frame: Baseline (0 hours), 2-hours post-dose
Percentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose
Pain freedom was defined as an NRS score of zero at 2 hours post-dose (yes or no). TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."
Time frame: Baseline (0 hour) to 2-hours post-dose
Time to Onset of Meaningful Pain Relief
Time to onset of meaningful pain relief post-dose is defined as the first nominal timepoint at which a 30% reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.
Time frame: Baseline (0 hours) up to 24 hours post-dose
Time to Onset of Initial Pain Relief
Time to onset of initial pain relief post-dose is defined as the first nominal timepoint at which a 1-point reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.
Time frame: Baseline (0 hour) to 24 hours post-dose
Percentage of Participants Using Rescue Medication Within 24 Hours Post-Dose
Rescue medications included any non-study medication recorded on the rescue medication case report form (CRF) with complete medication dates, and either (1) medication date/time is after the study drug start date/time if the medication time and study drug start time are both not missing, or (2) medication date is on or after study drug start date if the medication time or study drug start time is missing.
Time frame: Through 24 hours post-dose
A total of 126 participants were enrolled in the study. Only 87 participants were randomized to treatment and only 71 participants were treated.
| Milestone | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Started | 44 | 43 |
| Treated | 39 | 32 |
| Completed | 39 | 32 |
| Not completed | 5 | 11 |
| Withdrew: Randomized but not treated | 5 | 11 |
The SPID-2 was calculated by multiplying the pain intensity difference (PID) score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 2 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45-, 60-, 90- and 120-minutes post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-2 was: -12 (best) to 8 (worst). Lower SPID-2 score = more improvement from pain. SPID-2 Best is 2 hours\*-6 = -12 (assuming 0 pain intensity score \[pain-free\] for each timepoint) and 2) Worst is 2 hours\*4 = 8 (assuming 10 pain intensity score \[worst imaginable pain\] for each timepoint).
| Units on a scale | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Sum of Pain Intensity Difference (SPID) From Baseline to 2-Hours Post-dose (SPID-2) | -3.82 (-5.12 to -2.51) | -3.67 (-5.14 to -2.20) |
The SPID-24 was calculated by multiplying the PID score at each post-dose timepoint by the duration (in hours) since the preceding timepoint, then summing the values over the 24 hours. Participants indicated pain using e-diary at each timepoint (0, 15, 30, 45, 60, 90 and 120 minutes and 4-, 8-, and 24-hours post-dose) on an NRS score ranging from 0 (no pain) to 10 (worst imaginable pain). PID: calculated by finding the difference between the NRS score at each timepoint from the baseline NRS score (PID range is -6 \[best\] to 4 \[worst\]). Assuming a baseline pain intensity score of 6, possible score range of SPID-24 was: -144 (Best) to 96 (worst). Lower SPID-24 score = more improvement from pain. SPID-24 best and worst scores were calculated as: 1) Best is 24 hours\* -6 = -144 (assuming 0 pain intensity score for each timepoint) and 2) Worst is 24 hours\*4 = 96 (assuming 10 pain intensity score for each timepoint).
| Unit on a scale | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| SPID From Baseline to 24-Hours Post-dose (SPID-24) | -104.66 (-125.89 to -83.44) | -109.79 (-133.65 to -85.92) |
TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."
| Units on a scale | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Change From Baseline in NRS Score at 2-Hours Post-Dose | -3.08 (-3.89 to -2.26) | -3.28 (-4.19 to -2.38) |
Pain freedom was defined as an NRS score of zero at 2 hours post-dose (yes or no). TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain."
| Percentage of participants | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Percentage of Participants Who Experienced Pain Freedom at 2-Hours Post-Dose | 10.3 (0.7 to 19.8) | 15.6 (3.0 to 28.2) |
Time to onset of meaningful pain relief post-dose is defined as the first nominal timepoint at which a 30% reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.
| Minutes | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Time to Onset of Meaningful Pain Relief | 91.3 (56.0 to 233.6) | 120.3 (62.4 to 233.2) |
Time to onset of initial pain relief post-dose is defined as the first nominal timepoint at which a 1-point reduction of pain from baseline on NRS is achieved. TMD pain was assessed using an NRS score ranging in integers from 0 to 10, with 0 being "no pain" and 10 being "worst imaginable pain." Kaplan-Meier method was used for analysis.
| Minutes | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Time to Onset of Initial Pain Relief | 45.3 (30.5 to 54.7) | 45.2 (26.0 to 57.8) |
Rescue medications included any non-study medication recorded on the rescue medication case report form (CRF) with complete medication dates, and either (1) medication date/time is after the study drug start date/time if the medication time and study drug start time are both not missing, or (2) medication date is on or after study drug start date if the medication time or study drug start time is missing.
| Percentage of participants | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| Percentage of Participants Using Rescue Medication Within 24 Hours Post-Dose | 10.3 (0.7 to 19.8) | 6.3 (0.0 to 14.6) |
Collected over Randomization up to 7 days after study medication administration (maximum up to 52 days, if study medication took on 45th day post randomization, single dose was to be administered on any day from randomization to 45 days post randomization, only when NRS>=6). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rimegepant (BHV3000) | 0/39 (0%) | 0/39 (0%) | 1/39 (2.6%) |
| Placebo | 0/32 (0%) | 0/32 (0%) | 3/32 (9.4%) |
| Event | Rimegepant (BHV3000) | Placebo |
|---|---|---|
| PainGeneral disorders | 0/39 | 1/32 |
| HypertransaminasaemiaHepatobiliary disorders | 0/39 | 1/32 |
| HypoaesthesiaNervous system disorders | 0/39 | 1/32 |
| Bundle branch block rightCardiac disorders | 1/39 | 0/32 |
Analysis population included participants who were enrolled and received at least 1 dose of study medication. Baseline characteristics tabulated by the treated analysis set.
| Age, Continuous(Years) | Rimegepant (BHV3000) | Placebo | Total |
|---|---|---|---|
| Mean | 43.1 ± 13.93 | 38.6 ± 12.53 | 41.1 ± 13.42 |
| Sex: Female, Male(Participants) | Rimegepant (BHV3000) | Placebo | Total |
|---|---|---|---|
| Female | 30 | 25 | 55 |
| Male | 9 | 7 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Rimegepant (BHV3000) | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 28 | 21 | 49 |
| Not Hispanic or Latino | 11 | 11 | 22 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Rimegepant (BHV3000) | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 36 | 30 | 66 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from May 2022 to primary completion in May 2023, 12 months.
Results were first posted in May 2024, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rimegepant
Temporomandibular Joint Disorders →